Our sister site, Drug Delivery Business News, reported today that the company, founded by a trio with leadership experience across the diabetes industry, has kicked off a study for a new entry into the patch pump space.
Luna, the company’s patch pump system, delivers micro-doses of insulin while the user sleeps. The company designed it to transform nighttime glucose management
According to the company, the patch pump offers the “simplest onboarding experience” of any automated insulin delivery system. It also has the first algorithm designed for use with insulin pens, the company’s co-founder John Sjölund said in a blog post.
“We’re thrilled to announce the launch of our pivotal trial for Luna, our innovative automated insulin delivery system designed to transform nighttime glucose management,” the company wrote in a LinkedIn post. “This is a crucial step in our journey to provide safer, more effective solutions for those needing insulin therapy.
Sjölund founded Luna alongside Jon Brilliant, who co-founded Bigfoot Biomedical (acquired by Abbott), and Sean Saint, Beta Bionics CEO. Sjölund, himself Luna’s CEO, co-founded and led Timesulin as CEO until its acquisition by Bigfoot Biomedical.
Get the full story at our sister site, Drug Delivery Business News.
